| (210) | Number of the EPO application | 21182842 |
| (220) | Filing date of the EPO application | 2016.07.01 |
| (80) | EPO patent specification publication (B) | EPB nr. 14/2023, 2023.04.05 |
| (110) | EPO patent number | 3954690 |
| (21) | Number of the application | e 2022 0994 |
| (71) | Name(s) of applicant(s), code of the country | Acerta Pharma B.V., NL; |
| (72) | Name(s) of inventor(s), code of the country | BLATTER Fritz, CH;
INGALLINERA Tim, US;
BARF Tjeerd, NL;
ARET Edwin, NL;
KREJSA Cecile, US;
EVARTS Jerry, US; |
| (73) | Name(s) of owner(s), code of the country | ACERTA Pharma B.V., NL; |
| (54) | Title of the invention | Solid forms and formulations of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide |
| (13) | Kind-of-document code | A1 |
| (51) | International Patent Classification | C07D 487/04 (2006.01.01); A61K 31/4985 (2006.01.01); A61P 35/00 (2006.01.01) |
| (19) | Country | NL |
| (41) | Date of publication of the application | 2022.09.30 |
| (30) | Priority | 201562188468 P, 2015.07.02, US; 201562271708 P, 2015.12.28, US |